Instructions for Laritylene lozenges, blister with mint flavor, No. 20
Composition
active ingredients: dequalinium chloride, dibucaine hydrochloride;
1 lozenge contains dequalinium chloride in terms of 100% substance 0.25 mg, dibucaine hydrochloride in terms of 100% substance 0.03 mg;
excipients:
mint-flavored tablets: sorbitol (E 420), talc, colloidal silicon dioxide, magnesium stearate, peppermint flavoring, peppermint oil;
mint and raspberry flavored tablets: sorbitol (E 420), talc, colloidal silicon dioxide, magnesium stearate, raspberry flavoring, peppermint oil;
mint and lemon flavored tablets: sorbitol (E 420), talc, colloidal silicon dioxide, magnesium stearate, lemon flavoring, peppermint oil.
Dosage form
Tablets for resorption.
Main physicochemical properties: white round tablets with a bevel on both sides and a score on one side.
Pharmacotherapeutic group
Drugs used for throat diseases.
ATX code R02A.
Pharmacological properties
Pharmacodynamics
As a bactericidal and fungistatic substance, dequalinium chloride acts on microorganisms that cause mixed infections of the oral cavity and throat. The spectrum of action of this local chemotherapeutic agent is broad and includes most gram-positive and gram-negative bacteria, as well as fungi, spirochetes and pathogenic microorganisms that cause mixed infections of the oral cavity and throat. The accumulation of dibucaine hydrochloride in the body relieves the pain symptom that accompanies infections of the oral cavity and throat.
Microorganisms resistant to dequalinium chloride are unknown.
Does not cause caries.
Pharmacokinetics
The main active ingredient is absorbed in very small amounts.
Indication
Local treatment of acute inflammatory diseases of the oral cavity and throat: gingivitis, ulcerative and aphthous stomatitis, tonsillitis, laryngitis and pharyngitis. Laritylen® is also recommended for use in the presence of unpleasant breath odor.
Laritylen® can be used in cases of mixed infection of the oral cavity and throat (on the recommendation of a doctor); as an auxiliary drug in the treatment of catarrhal angina, lacunar angina and Plaut-Vincent angina; in case of candidiasis of the oral cavity and pharynx.
Recommended in the postoperative period after tonsillectomy and tooth extraction.
Contraindication
Hypersensitivity to any of the ingredients of the medicinal product. Allergy to quaternary ammonium compounds (e.g. benzalkonium chloride).
Interaction with other medicinal products and other types of interactions
The antibacterial activity of dequalinium is reduced when used simultaneously with anionic surfactants, for example in toothpaste. The use of the drug should not be combined with the intake of cholinesterase inhibitors.
Application features
Since Laritylen® does not contain sugar, it is suitable for use by diabetics.
The medicinal product contains sorbitol and should not be used in patients with rare hereditary diseases such as fructose intolerance. Use with caution in patients with low plasma cholinesterase levels.
Use during pregnancy or breastfeeding
Pregnancy. According to available data, no controlled studies have been conducted. In these circumstances, Laritylen® can be used during pregnancy after consultation with a doctor, if the therapeutic effect outweighs the possible risk to the fetus.
Breastfeeding. According to available data, no clinical studies have been conducted on the penetration of active substances into breast milk. The drug is not recommended for use during breastfeeding.
Ability to influence reaction speed when driving vehicles or other mechanisms
According to available data, no studies have been conducted on the effect of the drug on the ability to drive and use machines. However, the likelihood that Laritylen® may have any negative effect on this ability is very small.
Method of administration and doses
Adults and children aged 12 and over
Prescribe 1 tablet every 2 hours, after the symptoms of inflammation have subsided - 1 tablet every 4 hours.
For children aged 4 and over
Prescribe 1 tablet every 3 hours, after the symptoms of inflammation have subsided - 1 tablet every 4 hours.
The maximum daily dose is 10–12 tablets during the acute phase and 6 tablets after the inflammatory symptoms have disappeared.
The tablets should be sucked slowly, without chewing. The duration of treatment is determined by the doctor individually. The patient should consult a doctor if the symptoms have not disappeared or worsened after 5 days of treatment with the drug.
Children
The drug in this dosage form is not prescribed to children under 4 years of age.
Overdose
Treatment of overdose is symptomatic; if necessary, enveloping agents can be used.
Do not induce vomiting or perform gastric lavage - these measures are not advisable.
Adverse reactions
Sometimes hypersensitivity reactions may occur after using the drug, for example: rash, itching, burning sensation, irritation of the mucous membrane of the mouth and throat. In rare cases, namely in case of abuse, ulcers and necrosis may occur. In case of any unusual reactions, you should stop using the drug and be sure to consult a doctor about further therapy.
Reporting adverse reactions after the registration of a medicinal product is important. This allows monitoring of the benefit/risk ratio when using this medicinal product. Medical and pharmaceutical professionals, as well as patients or their legal representatives, should report all cases of suspected adverse reactions and lack of efficacy of the medicinal product via the Automated Information System for Pharmacovigilance at the link: https://aisf.dec.gov.ua/.
Expiration date
3 years.
Storage conditions
Store in original packaging at a temperature not exceeding 25 ° C. Keep out of the reach of children.
Packaging
10 tablets in a blister, 1 or 2 or 4 blisters in a pack.
Vacation category
Without a prescription.
Producer
PJSC "Kyivmedpreparat".
Location of the manufacturer and its business address
Ukraine, 01032, Kyiv, Saksaganskoho St., 139.
